Ocular Therapeutix (OCUL) Tops Q3 EPS by 11c
- Discover Financial Services (DFS) Announces CEO Resignation
- Timken (TKR) Appoints Tarak Mehta as New CEO
- Crude Inventory Increases 3.2 Million Barrels
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Many senior Amazon employees won't get cash raises this year - Fortune
Ocular Therapeutix™ Reports Third Quarter 2016 Financial Results and Provides Corporate Update
November 9, 2016 7:00 AM ESTPreparing to Resubmit NDA for DEXTENZA for the Treatment of Ocular Pain Occurring After Ophthalmic Surgery to FDA by the End of 2016
Began Enrollment in First Phase 3 Clinical Trial with OTX-TP (Sustained Release Travoprost) for the Treatment of Glaucoma and Ocular Hypertension
Entered Into Strategic Collaboration with Regeneron to Develop Sustained Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases
Conference Call Today at 8:30 am Eastern Time
BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ:... More